Related Experiment Video
Updated: May 5, 2026
07:01
Direct Mouse Trauma/Burn Model of Heterotopic Ossification
Published on: August 6, 2015
9.8K
Heterotopic Ossification: Molecular Drivers, Subtype-Specific Mechanisms, and Translational Therapeutic Advances
Sihong Chen1,2, Hui Lin1
1School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Biomolecules
|May 4, 2026
Summary
Heterotopic ossification (HO) involves pathological bone formation in soft tissues. This review details signaling pathways in FOP, POH, and tHO subtypes, proposing targeted therapies for improved patient outcomes.
Area of Science:
- Pathological bone formation in non-skeletal tissues.
- Understanding of heterotopic ossification (HO) subtypes.
Background:
- HO severely impacts mobility and quality of life.
- Current therapies for HO have high recurrence and side effects.
- Insufficient systematic analysis of signaling networks across HO subtypes.
Purpose of the Study:
- Synthesize recent advances in HO pathogenesis.
- Integrate key signaling crosstalk in HO.
- Highlight novel, subtype-specific therapies for HO.
Main Methods:
- Review of recent scientific literature on HO pathogenesis.
- Analysis of signaling pathways in Fibrodysplasia Ossificans Progressiva (FOP), Progressive Osseous Heteroplasia (POH), and traumatic HO (tHO).
- Identification and evaluation of emerging therapeutic strategies.
Main Results:
- FOP linked to ACVR1 mutations disrupting BMP/Activin A signaling.
- POH associated with GNAS mutations affecting Hedgehog signaling.
- tHO involves trauma-induced inflammation/hypoxia activating BMP/TGF-β pathways.
- Key signaling crosstalk (BMP-YAP-IHH) identified.
Conclusions:
- Novel therapies like ACVR1 inhibitors and RARγ agonists show promise.
- Subtype-specific efficacy is crucial for effective HO management.
- A stratified, mechanism-based framework can advance precision therapy for HO.
